1. Home
  2. CRSP vs APGE Comparison

CRSP vs APGE Comparison

Compare CRSP & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$56.49

Market Cap

5.1B

Sector

Health Care

ML Signal

HOLD

Logo Apogee Therapeutics Inc.

APGE

Apogee Therapeutics Inc.

HOLD

Current Price

$78.25

Market Cap

4.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
APGE
Founded
2013
2022
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
4.7B
IPO Year
2016
2023

Fundamental Metrics

Financial Performance
Metric
CRSP
APGE
Price
$56.49
$78.25
Analyst Decision
Buy
Strong Buy
Analyst Count
19
10
Target Price
$71.50
$101.89
AVG Volume (30 Days)
1.7M
1.0M
Earning Date
02-10-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$38,337,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$718.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$30.04
$26.20
52 Week High
$78.48
$80.99

Technical Indicators

Market Signals
Indicator
CRSP
APGE
Relative Strength Index (RSI) 51.43 63.04
Support Level $53.37 $75.02
Resistance Level $60.73 $80.24
Average True Range (ATR) 2.33 3.29
MACD 0.12 -0.41
Stochastic Oscillator 47.39 77.09

Price Performance

Historical Comparison
CRSP
APGE

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About APGE Apogee Therapeutics Inc.

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Share on Social Networks: